New hope for Hard-to-Treat cancers: first human trial of targeted drug begins
NCT ID NCT04145622
First seen Oct 31, 2025 · Last updated May 17, 2026 · Updated 32 times
Summary
This study tests a new drug, ifinatamab deruxtecan, in people with advanced solid tumors that have not been cured by other treatments. It is the first time this drug is being used in humans. The study has two parts: first, to find the safest dose, and second, to see how well the drug works. Participants who benefit may continue treatment unless their disease worsens or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aichi Cancer Center Hospital
RECRUITINGAichi, 464-8681, Japan
Contact
-
Cancer Institute Hospital of JFCR
RECRUITINGTokyo, 135-8550, Japan
Contact
-
Cedars-Sinai Medical Center- Samuel Oschin Comprehensive Cancer Institute
WITHDRAWNLos Angeles, California, 90048, United States
-
Columbia University Medical Center
WITHDRAWNNew York, New York, 10032, United States
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact
-
Florida Cancer Specialists
WITHDRAWNOrlando, Florida, 32804, United States
-
Florida Cancer Specialists
RECRUITINGSarasota, Florida, 34232, United States
Contact
-
Henry Ford Hospital
ACTIVE_NOT_RECRUITINGDetroit, Michigan, 48202, United States
-
Hokkaido University Hospital
RECRUITINGHokkaido, 060-8648, Japan
Contact
-
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact
-
Kindai University Hospital
RECRUITINGŌsaka-sayama, 589-8511, Japan
Contact
-
MDACC (MD Anderson Cancer Center)
ACTIVE_NOT_RECRUITINGHouston, Texas, 77030, United States
-
Memorial Sloan-Kettering Cancer Center
ACTIVE_NOT_RECRUITINGNew York, New York, 10065, United States
-
National Cancer Center Hospital
RECRUITINGTokyo, 104-0045, Japan
Contact
-
National Cancer Center Hospital East
RECRUITINGChiba, 277-8577, Japan
Contact
-
Osaka University Hospital
RECRUITINGOsaka, 565-0871, Japan
Contact
-
SCRI Oncology Partners
ACTIVE_NOT_RECRUITINGNashville, Tennessee, 37203, United States
-
Saitama Cancer Center
RECRUITINGSaitama, 362-0806, Japan
Contact
-
Sarah Cannon Research Institute at HealthONE
RECRUITINGDenver, Colorado, 80218, United States
Contact
-
Shizuoka Cancer Center Hospital and Research Institute
RECRUITINGShizuoka, 411-8777, Japan
Contact
-
Showa University Hospital
RECRUITINGTokyo, 142-8666, Japan
Contact
-
Sidney Kimmel Cancer Center - Thomas Jefferson
WITHDRAWNPhiladelphia, Pennsylvania, 19107, United States
-
Tennessee Oncology
RECRUITINGNashville, Tennessee, 37203, United States
Contact
-
The Ohio State University
WITHDRAWNColumbus, Ohio, 43210, United States
-
Washington University
ACTIVE_NOT_RECRUITINGSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.